Barcelona Vaccine Forum

Active Immunotherapeutics Forum

• Dr Marie-Paule Kieny, Director, Initiative for Vaccine Research, World Health Organization
• Dr David Salisbury, Director of Immunisation, UK Department of Health
• Dr Rino Rappuoli, Global Head Vaccines Research, Novartis Vaccines & Diagnostics
  
• Dr Robin Robinson, Director & Deputy Assistant Secretary, Biomedical Advanced
  Research & Development Authority (BARDA), Office of the Assistant Secretary for Preparedness & Response (ASPR), US Department of Health & Human Services
  
• Dr Allan P. Jarvis, Vice President, Corporate Development, sanofi pasteur
• Dr Beth P. Bell, Associate Director for Science, National Center for Immunization & Respiratory Diseases, CDC
• Dr Udit Batra, Head, Global Public Health & Market Access, Novartis Vaccines & Diagnostics
  
• Dr N. Regina Rabinovich, Director, Infectious Diseases Development, The Bill & Melinda Gates Foundation
• Yves Leurquin, Executive Vice President, International & Government Affairs, Crucell NV
• Theresa Finn, PhD, Associate Director for Regulatory Policy, OVRR, CBER, US Food & Drug Administration
• Dr Shen Xinliang, Director-General, National Vaccine & Serum Institute & National Engineering Research Center for Novel Vaccines, China
• Dr Norbert Hehme, Vice President, Global External Relations GIO, GlaxoSmithKline Biologicals & Chair, IFPMA Influenza Vaccine Supply International Task Force
• Dr Peter Richardson, Head of Biologicals, Quality of Medicines Unit, European Medicines Agency
• Dr Ernst C. Soethout, Senior Research Scientist, Netherlands Vaccine Institute
  
• Dr Derek O'Hagan, Vice President, Global Head, Vaccine Delivery Research, Novartis Vaccines & Diagnostics
• Dr John W. Shiver, Vice President, Global Vaccines Discovery & Basic Research, Merck Research Laboratories
• Dr Ted Bianco, Director - Technology Transfer, The Wellcome Trust
• Dr Andrew Baum, Managing Director, Equity Research, Morgan Stanley
• Una S. Ryan, OBE, PhD, President & CEO, Diagnostics For All
• Dr Rahul Singhvi, President & CEO, Novavax, Inc
• Jan Reid, Senior Director, Vaccines Licensing, Pfizer R&D Business Development
• Dr Antoon Gijsens, Policy Officer, Unit SANCO C3 - Health Threats, European Commission
• Dr Philippe Pouletty, Co-Founder & General Partner, Life Sciences, Truffle Capital
• Dr Sanjay Singh, CEO, Gennova Biopharmaceuticals Limited
• Dr Alan Shaw, President & Chief Executive Officer, VaxInnate
• Peter Welford, CFA, Director, European Healthcare Equity Research, Jefferies International Limited
• Professor Alexander Von Gabain, Strategic Advisor to the Board, Intercell AG
• W. Neil Palmer, President & Principal Consultant, PDCI Market Access
• Staph Leavenworth Bakali, CEO, Genocea Biosciences
• Dr Tyler Martin, Chief Medical Officer, DynaVax Corporation
  
• Dr Germie van den Dobbelsteen, Program Manager, Bacterial Vaccines, Netherlands Vaccine Institute
• Dr Susan W. Barnett, Senior Director, Senior Project Leader, Viral Vaccine Research, Novartis Vaccines and Diagnostics, Inc
• Dr Anne De Groot, CSO & CEO, EpiVax, Inc
• Dr Marco Cavaleri, Head of Anti-Infectives & Vaccines, Safety & Efficacy of Medicines Unit, European Medicines Agency
• Dr Alexandra Löw-Baselli, Director of Clinical Development, Vaccines, Baxter BioScience
• Professor Angus Dalgleish, Professor of Oncology, St George's, University of London
• Professor Nikolai Petrovsky, CSO, Vaxine Pty Ltd
  
• Dr Wilfried A. M. Bakker, Senior Research Scientist, Netherlands Vaccine Institute
• Dr Manon Cox, COO, Protein Sciences Corporation
• Dr Ronald W. Ellis, Senior Vice President & Chief Technology Officer, NasVax Ltd, Israel
• Katharina Hartmann, MScPharm, Head of Pharmacovigilance, Crucell Switzerland AG
• Dr Jennifer R. Hannesschlager, Principal, Tiber Creek Partners, LLC
  
• Dr Frank Vandendriessche, Director, Regulatory Affairs, Europe, MSD Europe
• Dr David Kirke, Associate Director, ERA Consulting

• Dr Steve Gracheck, Executive Director, Vaccine Research – La Jolla, Pfizer Global R&D
• Dr Mitchell H. Gold, President & CEO, Dendreon Corporation
• Dr Axel Hoos, Medical Lead, Immunology/Oncology, Bristol-Myers Squibb
• Dr Helen Sabzevari, Global Head of Oncology-Immunotherapy, Merck Serono
• Wim Tiest, Director, Head, Portfolio Strategy & Business Operations, Immunotherapeutics Business Unit, GlaxoSmithKline Biologicals
• Poul Sørensen PhD, Vice President, Global Research, ALK
• Dr Samir N. Khleif, Head, Cancer Vaccine Section, NCI
• Jens-Peter Marschner, MD, Head, Immunologicals Programs, Global Early & Clinical Development Units Oncology, Merck KGaA
• Charles A. Nicolette, PhD, Chief Scientific Officer, Vice President, R&D, Argos Therapeutics, Inc
• Dr David L. Urdal, CSO, Dendreon Corporation
• Dr Thomas Hinz, Paul-Ehrlich-Institut
• Neil L. Berinstein MD, Chief Scientific Officer, IRX Therapeutics
• Dr Thomas A. Davis, CMO & Senior Vice President, Clinical Development, Celldex Therapeutics
  
• Hideki Garren, MD, PhD, Executive Vice President, COO, CSO & Co-Founder, Bayhill Therapeutics
• Dr Susan W. Barnett, Senior Director, Senior Project Leader, Viral Vaccine Research, Novartis Vaccines and Diagnostics, Inc
• Fernando Ulloa-Montoya, PhD, Head of Molecular Biology Technology Group, Cancer Immunotherapy, GlaxoSmithKline Biologicals
• Professor Alexander Von Gabain, Strategic Advisor to the Board, Intercell AG
• Markus Muenz, Group Leader, EpCAM Research, Micromet AG
• Dr Jean-Yves Bonnefoy, Vice President, R&D, Transgene SA
• Dr Philippe Pouletty, Co-Founder & General Partner, Life Sciences, Truffle Capital
• Dr Martin Bachmann, CSO, Cytos Biotechnology AG
• Dr Harpreet Singh, CSO, immatics biotechnologies GmbH
• Judith Quinlan, Vice President, Adaptive Trials, Cytel
• Reiner Laus, MD, President & Chief Executive Officer, BN ImmunoTherapeutics
• Philippe Moingeon PhD, Vice President, R&D, Stallergenes SA
• Dr Joyce Frey-Vasconcells, Executive Director, PharmaNet Consulting, PharmaNet Development Group
• Professor Angus Dalgleish, Professor of Oncology, St George's, University of London
• Pierre Vandepapelière, MD, PhD, Chief Medical Officer, Neovacs SA
• Daniel L. Levey, PhD, Senior Director, Business Development, Antigenics Inc
• Professor Dr C. J. M. Melief, Professor of Immunology, Department of Immunohematology & Blood Transfusion, Leiden University Medical Center
• Carlos F. Santos PhD, Director of Regulatory Affairs & Product Development, Accentia Biopharmaceuticals / Biovest International
• Dr Ronald W. Ellis, Senior Vice President & Chief Technology Officer, NasVax Ltd, Israel
• Dr Habib Fakhrai, Executive Vice Chairman of the Board & CSO, NovaRX
• Dr Ingólfur Johannessen, Clinical Lecturer in Virology, College of Medicine & Veterinary Medicine, University of Edinburgh & Royal Infirmary of Edinburgh
• Dr Joseph Sinkule, Founder, Director & CSO, Apthera, Inc
• Dr Ulrich Granzer, Granzer Regulatory Consulting & Services